USA - NYSE:GMED - US3795772082 - Common Stock
The current stock price of GMED is 83.89 USD. In the past month the price increased by 48.29%. In the past year, price increased by 3.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
GLOBUS MEDICAL INC - A
2560 General Armistead Ave
Audubon PENNSYLVANIA 19403 US
CEO: David M. Demski
Employees: 5300
Phone: 16109301800
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
The current stock price of GMED is 83.89 USD. The price increased by 35.94% in the last trading session.
GMED does not pay a dividend.
GMED has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
GLOBUS MEDICAL INC - A (GMED) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
GLOBUS MEDICAL INC - A (GMED) currently has 5300 employees.
GLOBUS MEDICAL INC - A (GMED) will report earnings on 2026-02-10, after the market close.
ChartMill assigns a technical rating of 8 / 10 to GMED. When comparing the yearly performance of all stocks, GMED is one of the better performing stocks in the market, outperforming 85.8% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to GMED. Both the health and profitability get an excellent rating, making GMED a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS increased by 22.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.58% | ||
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| Debt/Equity | 0 |
21 analysts have analysed GMED and the average price target is 81.91 USD. This implies a price decrease of -2.37% is expected in the next year compared to the current price of 83.89.
For the next year, analysts expect an EPS growth of 4.11% and a revenue growth 14.02% for GMED